Con la semaglutida, la farmacéutica danesa Novo Nordisk es ya la empresa más valiosa ... con más de 100 prototipos de nuevos fármacos en estudio (12 en fases avanzadas), alguno puede culminar ...
Los fabricantes europeos de medicamentos como Ozempic y productos para el cuidado de la piel como Cetaphil han expresado su ...
Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...
Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...
Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback